Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-2: maridebart cafraglutide versus placebo in adults with type 2 diabetes mellitus and overweight or obesity
2024-515523-11-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Jun 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing Maridebart cafraglutide with Placebo (2 arms). Primary endpoint: Percent change from baseline in body weight at week 72. Planned start Jun 2025; status: authorised.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-515523-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515523-11-00.